Navigation Links
TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
Date:4/2/2009

two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.tptxinc.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the ability for TorreyPines to complete a strategic transaction, including a possible sale of the Company. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2008 and TorreyPines other SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TorreyPines undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company Contact:
    Paul Schneider
    TorreyPines Therapeutics, Inc.
    858-623-5665, x125
    pschneider@TPTXinc.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
2. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
3. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
4. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
5. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
6. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
7. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
8. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
9. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
10. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
11. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Pipette.com announces their Holiday in ... submit their #HolidayInTheLab pictures for a chance to win ... For those struggling to think of a holiday gift ... the Lab Contest provides the ideal holiday presents. The ... send pictures of their chemistree, holiday sweaters, as well ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced ... , a network of more than 20 contributing ... have fast access to a national pool of frozen ... Fertility Associates of Memphis is the only fertility clinic ... , Dr. William Kutteh , director of Fertility ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3
... The nation's dysfunctional healthcare system may undermine any ... electronic health records, according to a featured speaker at this ... Grossman Dr. Jeff Grossman, president and CEO of the ... the role of IT in healthcare delivery. As he outlined ...
... as much as buildings and there are many stakeholders. But ... involved and excited, said presenters at the Digital Healthcare ... absolutely essential," said Peter Strombom, CIO of Meriter Hospital ... don't feel they're being heard, you're going to have trouble ...
... Santiago that research projects on his campus will get ... laugh at you. , ,"Let's get real," Santiago told ... of higher education in Wisconsin. "(UW-Milwaukee research programs) are ... periods of their evolution." , ,Likewise, don't suggest to ...
Cached Biology Technology:U.S. health system could undermine EHR progress 2U.S. health system could undermine EHR progress 3Healthcare leaders tell how they rally stakeholders around IT 2Why Milwaukee needs its own thriving research base 2Why Milwaukee needs its own thriving research base 3
(Date:12/22/2014)... -- The 2014 Holiday Season may be the brightest ... Intelligence reports that the long anticipated floodgates for ... that intensifying demand for smart phones, tablets, and ... a global market of 2.5 billion users with ... According to Maxine Most , ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and ... addition of the "Micro Market Monitor: North America ... http://photos.prnewswire.com/prnh/20130307/600769 ... grow at a CAGR of 3.6% from 2014 to ... in this market, Canada is ...
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ... team and bring LaunchKey to market in 2015. ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... - Resistant wheat plants stave off attacks by Hessian fly ... to absorb nutrients, according to a study by Purdue University ... midguts - similar to human intestines - were observed in ... midgut function. Those that were given nothing to eat showed ...
... Allergies and Infectious Diseases (NIAID), part of the National ... totaling $15,254,919 to Tulane University for its ongoing efforts ... viral disease that threatens hundreds of thousands of people ... potential bioterrorism threat. The contract will include collaboration ...
... seems, are going on a diet, while others have ... rapidly rising temperatures due to global climate change, speculates ... Zoology, who has been measuring the evolving body sizes ... is most extreme. , Changes are happening primarily in ...
Cached Biology News:Resistant wheat goes for the gut to protect against Hessian flies 2Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2Animals cope with climate change at the dinner table 2
Complexin-1/2 (FL-134)...
...
... (human, porcine) Endogenous potent vasoconstrictor ... receptor and modulates vascular tonus. ET-1, ET-2, ... distinct endothelin genes. ET-2 and ET-3 are ... and six amino acids, respectively. All three ...
HNF-1 Purified Anti-Mouse, Anti-Rat, Anti-Rabbit, Anti-Human clone 2, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: